FDA and Private Enforcement, State Board Compliance, and the Future of Telehealth Prescribing
Presented by: American College of Apothecaries (ACA)
Frier Levitt Partner Jesse Dresser and attorney Edgar Asabey will present an upcoming webinar hosted by the American College of Apothecaries (ACA) titled “Legal Insights into GLP-1 and Peptide Compounding in 2026: FDA and Private Enforcement, State Board Compliance, and the Future of Telehealth Prescribing.”
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape. This program will provide a practical legal update on compounding compliance for 503A pharmacies, 503B outsourcing facilities, telehealth platforms, and marketing teams involved in compounded GLP-1 and peptide products.
Learning Objectives
- Understand the regulatory framework governing 503A pharmacies, 503B outsourcing facilities, telehealth providers, and marketing activities related to compounded GLP-1 and peptide products.
- Evaluate current enforcement trends, including FDA oversight, State Board investigations, and private litigation, and develop practical response strategies.
- Assess the compliance impact of the GLP-1 shortage ending, including prescribing, dispensing, compounding, and promotional considerations.
- Identify key risk-mitigation strategies for telehealth prescribing models and related pharmacy operations in a heightened enforcement climate.
Attendees will gain practical, actionable guidance to help pharmacists, pharmacy technicians, telehealth professionals, and marketers of compounded GLP-1s and peptides assess regulatory risk, respond to FDA and State Board inquiries, and strengthen internal compliance practices in this increasingly scrutinized and evolving landscape.
